AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
TG Therapeutics Q2 2025: Unpacking Contradictions in Market Share, Subcutaneous Trials, and Payer Demand Trends
Generated by AI AgentEarnings Decrypt
Monday, Aug 4, 2025 10:24 am ET1min read
Aime SummaryMarket share and patient enrollments, subcutaneous trial design and timeline, market share and product market preferences, payer demand shift and product development strategy are the key contradictions discussed in TG Therapeutics' latest 2025Q2 earnings call.
BRIUMVI Commercial Performance:
- reported U.S. net sales for BRIUMVI in Q2 totaled approximately $139 million, exceeding internal expectations and building on robust growth in Q1, which translates to a 91% increase compared to the same period last year and 16% growth over Q1 2025.
- This strong performance is attributed to increased new patient enrollments, deeper penetration across academic institutions and community neurology practices, strong persistence and repeat prescribing, and a convenient twice-a-year infusion schedule.
Subcutaneous BRIUMVI Development:
- The development of subcu BRIUMVI is progressing, with the plan to initiate patient enrollment into the pivotal Phase III trial in the coming weeks.
- The advancement is driven by the potential to unlock access to the 35%-40% of the anti-CD20 market that prefers self-administered options and to position TG Therapeutics as the only company offering both IV and self-administered options.
Financial Growth and Revenue Outlook:
- TG Therapeutics reported total revenue of $141.1 million for Q2 2025, marking a 91% increase compared to the same period last year and a 16% growth over the first quarter.
- This growth is supported by commercial momentum, strategic investments, and the success of the national television campaign that increased patient awareness of BRIUMVI.
Increased Guidance for 2025:
- TG Therapeutics raised its full-year U.S. BRIUMVI net revenue guidance from $560 million to $570 million to $575 million for 2025.
- The increase is based on trends in new patient prescriptions and persistence of existing patients, reflecting the ongoing success of the launch and strategic investments in commercial efforts.
BRIUMVI Commercial Performance:
- reported U.S. net sales for BRIUMVI in Q2 totaled approximately $139 million, exceeding internal expectations and building on robust growth in Q1, which translates to a 91% increase compared to the same period last year and 16% growth over Q1 2025.
- This strong performance is attributed to increased new patient enrollments, deeper penetration across academic institutions and community neurology practices, strong persistence and repeat prescribing, and a convenient twice-a-year infusion schedule.
Subcutaneous BRIUMVI Development:
- The development of subcu BRIUMVI is progressing, with the plan to initiate patient enrollment into the pivotal Phase III trial in the coming weeks.
- The advancement is driven by the potential to unlock access to the 35%-40% of the anti-CD20 market that prefers self-administered options and to position TG Therapeutics as the only company offering both IV and self-administered options.
Financial Growth and Revenue Outlook:
- TG Therapeutics reported total revenue of $141.1 million for Q2 2025, marking a 91% increase compared to the same period last year and a 16% growth over the first quarter.
- This growth is supported by commercial momentum, strategic investments, and the success of the national television campaign that increased patient awareness of BRIUMVI.
Increased Guidance for 2025:
- TG Therapeutics raised its full-year U.S. BRIUMVI net revenue guidance from $560 million to $570 million to $575 million for 2025.
- The increase is based on trends in new patient prescriptions and persistence of existing patients, reflecting the ongoing success of the launch and strategic investments in commercial efforts.
Earnings Decrypt
Discover what executives don't want to reveal in conference calls
Latest Articles
ServiceTitan's Q3 2026: Contradictions Emerge on MAX Program, Residential HVAC GTV, AI Strategy, Tariff Impact, and Growth Strategy
Dec.05 2025
Rubrik's Q3 2026: Contradictions Emerge on Growth Strategy, Non-Cloud ARR, Market Position, and Identity Security
Dec.05 2025
Stitch Fix's 2026 Q1 Earnings Call: Contradictions Emerge on Gross Margins, Advertising Strategies, and Client Acquisition
Dec.05 2025
CooperVision's Q4 2025: Contradictions Emerge on Growth Expectations, Contact Lens Market Projections, MyDay Margins, Fertility Sales, and Inventory Dynamics
Dec.05 2025
Zumiez's Q3 2026: Contradictions in Skate Hardgoods, Private Label, Footwear, and Growth Outlook
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet